Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,912 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity.
Hirahara K, Onodera A, Villarino AV, Bonelli M, Sciumè G, Laurence A, Sun HW, Brooks SR, Vahedi G, Shih HY, Gutierrez-Cruz G, Iwata S, Suzuki R, Mikami Y, Okamoto Y, Nakayama T, Holland SM, Hunter CA, Kanno Y, O'Shea JJ. Hirahara K, et al. Among authors: okamoto y. Immunity. 2015 May 19;42(5):877-89. doi: 10.1016/j.immuni.2015.04.014. Immunity. 2015. PMID: 25992861 Free PMC article.
A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T. Motohashi S, et al. Among authors: okamoto y. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6079-86. doi: 10.1158/1078-0432.CCR-06-0114. Epub 2006 Oct 6. Clin Cancer Res. 2006. PMID: 17028247 Clinical Trial.
Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, Taniguchi M, Nakayama T, Okamoto Y. Uchida T, et al. Among authors: okamoto y. Cancer Immunol Immunother. 2008 Mar;57(3):337-45. doi: 10.1007/s00262-007-0373-5. Epub 2007 Aug 10. Cancer Immunol Immunother. 2008. PMID: 17690880 Free PMC article. Clinical Trial.
The induced regulatory T cell level, defined as the proportion of IL-10(+)Foxp3(+) cells among CD25(+)CD4(+) leukocytes, is a potential therapeutic biomarker for sublingual immunotherapy: a preliminary report.
Fujimura T, Yonekura S, Taniguchi Y, Horiguchi S, Saito A, Yasueda H, Nakayama T, Takemori T, Taniguchi M, Sakaguchi M, Okamoto Y. Fujimura T, et al. Among authors: okamoto y. Int Arch Allergy Immunol. 2010;153(4):378-87. doi: 10.1159/000316349. Epub 2010 Jun 18. Int Arch Allergy Immunol. 2010. PMID: 20559004 Clinical Trial.
Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy.
Asada S, Kuroda M, Aoyagi Y, Fukaya Y, Tanaka S, Konno S, Tanio M, Aso M, Satoh K, Okamoto Y, Nakayama T, Saito Y, Bujo H. Asada S, et al. Among authors: okamoto y. Am J Physiol Cell Physiol. 2011 Jul;301(1):C181-5. doi: 10.1152/ajpcell.00080.2011. Epub 2011 Apr 6. Am J Physiol Cell Physiol. 2011. PMID: 21471463 Free article.
NKT cells as an ideal anti-tumor immunotherapeutic.
Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, Taniguchi M. Fujii S, et al. Among authors: okamoto y. Front Immunol. 2013 Dec 2;4:409. doi: 10.3389/fimmu.2013.00409. Front Immunol. 2013. PMID: 24348476 Free PMC article. Review.
3,912 results